Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.

Areteia Therapeutics

The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies - Endpoints News

Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 - Business Wire

Bain goes big again, leading $350M round to fund oral challenger to blockbuster asthma biologics - Fierce Biotech

Areteia Therapeutics announces the appointments of Dr. Eric Bradford as Chief Medical Officer, and Robin Walker as Chief Legal Officer and Corporate Secretary 

03.09.23 

											French
											



											Turkish
											

North Carolina biotech tops $400M in funding for asthma treatment - The Business Journals

09.07.22 

											Spanish
											

Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma - MedCity News

Executive Voice: From big pharma to a bold bet on the future - The Business Journals

Aiolos Bio Launches With $245M As Asthma-Focused Funding Accelerates - Crunchbase News

Bain Capital backs new biotech startup developing oral asthma drug - BioPharma Dive



											Polish
											

Finance Watch: Big Money For Private Biopharma As Start-Up Areteia Raises $350m - insights.citeline.com

Knopp, Population Health Launch Areteia to Breathe New Life into Old Molecule - BioSpace

Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors - Business Wire

04.20.23 Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors - Business Wire



											Italian
											

Areteia Therapeutics Raises $350M To Create An Oral Asthma Treatment - Crunchbase News

Now Enrolling


              Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
            

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma - Business Wire

Dexpramipexole flourishes in EXHALE-1 asthma study - Clinical Trials Arena

02.15.24 Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors - BioSpace

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma 



											Korean
											


              Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors
            

01.03.24 EXHALE-4

Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma - Business Wire

Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer 

03.26.25 Areteia Therapeutics Granted ILAP Designation from UK MHRA for Oral Dexpramipexole for Eosinophilic Asthma - Business Wire

Asthma Therapeutics Market Size to Hit USD 45.96 Billion by 2033 - BioSpace

Areteia Therapeutics Raises Additional $75M in Series A Financing - FinSMEs

Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 - Business Wire

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding - Bain Capital

Areteia Therapeutics Announces Appointment of Elyse Stock, M.D. To Board of Directors - Business Wire

02.23.23 Driving innovation in respiratory health: Areteia’s 2025 milestones and future goals - Pharmaceutical Technology



											German
											


						
									About Areteia Therapeutics
					
					

02.13.24 Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 - BioSpace


                Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025
              



											Portuguese
											

09.22.22 Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma - Business Wire

EXHALE-3



											Chinese
											

EXHALE-2

Areteia Therapeutics announces the appointments of Dr. Eric Bradford as Chief Medical Officer, and Robin Walker as Chief Legal Officer and Corporate Secretary - Business Wire

01.09.25 Areteia begins subject dosing in eosinophilic asthma therapy trials - Clinical Trials Arena

Knopp helps create Areteia in a $350M deal to further develop an asthma drug - BioWorld Online


                Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors
              

Areteia’s dexpramipexole holds potential to redefine respiratory health: GlobalData - Express Pharma

Areteia Therapeutics

Business:

About: